UBS has confirmed its 'buy' recommendation for AstraZeneca PLC (LSE:AZN) and set a 12-month price target of 14,200p, expressing confidence in the prospects of its blood pressure medication, baxdrostat. AstraZeneca is working on baxdrostat as part of a new group of treatments known as aldosterone synthase inhibitors (ASIs).
AstraZeneca PLC is getting closer to its goal of reaching $80 billion in revenue by 2030, thanks to encouraging results from a trial of Imfinzi, as noted by analysts. Following the positive update on Friday, Shore Capital has reaffirmed its 'buy' rating, highlighting the successful combination of the drug with chemotherapy.
A new treatment that combines AstraZeneca PLC's drug Imfinzi with chemotherapy has shown encouraging results for patients with early-stage stomach and oesophageal cancer, reducing the chances of cancer returning after surgery. The MATTERHORN trial, a significant international study, examined if adding Imfinzi to regular chemotherapy before and after surgery could enhance patient results.
At the end of the last trading day, Astrazeneca (AZN) was priced at $77.47, which represents a decrease of 0.63% compared to the previous day.
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included the clinical trials report titled "Endothelin Receptor Antagonist - Pipeline Insight, 2025" in its collection.
WILMINGTON, Del.--(BUSINESS WIRE)--The complete results from the successful Phase III WAYPOINT trial revealed that TEZSPIRE® (tezepelumab-ekko), developed by AstraZeneca and Amgen, greatly decreased the severity of nasal polyps, the necessity for further surgery, and the use of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) when compared to a placebo.1,2 This information was published in the New England Journal of Medicine and was shared today during a late-breaking oral presentation at the American Academy of.
At the end of the last trading day, Astrazeneca (AZN) was priced at $76.21, which represents a 0.74% increase compared to the previous day.
Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included the report titled "Neurofibromatoses: Competitive Landscape" in its collection. This report offers a data-based summary of the present and future competition in treatments for Neurofibromatoses. In 2024, it is expected that there will be over 986,000 diagnosed cases of Neurofibromatoses in the 16 countries included in the analyst's epidemiological forecast.
AstraZeneca PLC (LSE:AZN) has gained £2 billion in market value following encouraging results from a trial of a breast cancer medication. The trial showed that the experimental drug, camizestrant, helped patients live longer without their condition getting worse, based on an interim analysis.
AstraZeneca, a leading pharmaceutical company, announced on Wednesday that its new treatment, camizestrant, has shown to enhance survival rates in patients with advanced breast cancer during a late-stage trial, while also preventing the disease from worsening.